RA Capital Nexus Fund III, L.P.
SEC-identified person · CIK 1883840 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Septerna, Inc. SEPN | Director | filed 2024 - 2026 |
| Artiva Biotherapeutics, Inc. ARTV | Director | filed 2024 - 2026 |
| Sionna Therapeutics, Inc. SION | Director | filed 2025 - 2026 |
| Parabilis Medicines, Inc. PBLS | Director | filed 2026 - 2026 |
| Bicara Therapeutics Inc. BCAX | Director | filed 2024 - 2026 |
| Eliem Therapeutics, Inc. ELYM | Director | filed 2024 - 2026 |
| Mineralys Therapeutics, Inc. MLYS | Director | filed 2023 - 2026 |
| Evommune, Inc. EVMN | Director | filed 2025 - 2026 |
| Spyglass Pharma, Inc. SPG | Director | filed 2026 - 2026 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.